Other Events ·
Valion Bio announces AFRRI will evaluate Entolimod for GI acute radiation syndrome efficacy
TIVCValion Bio, Inc.
The Armed Forces Radiobiology Research Institute (AFRRI) will evaluate the therapeutic efficacy of Valion Bio's lead drug candidate, Entolimod, in a fully funded study targeting gastrointestinal acute radiation syndrome. The decision follows positive safety findings and aims to determine if post-exposure treatment improves survival rates. Top-line results are anticipated in early December. Additionally, Valion Bio terminated General Counsel Melinda Lackey on October 30, 2026, paying her $26,750 in severance under a separation agreement. Valion Bio is a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation.